Drugs / Fenoterol

Trials 11 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05294965 Apr 2022 → Mar 2023 University Hospital, Basel, Switzerland Completed No outcome recorded
Phase 11 trial
Phase 1 NCT02054299 Apr 2013 → Feb 2016 University Medical Center Goettingen Completed No outcome recorded
Phase 38 trials
Phase 3 NCT02176200 Apr 2003 → Dec 2004 chronic obstructive pulmonary disease Boehringer Ingelheim Terminated No outcome recorded
Phase 3 NCT02176187 Apr 2003 → Dec 2004 chronic obstructive pulmonary disease Boehringer Ingelheim Terminated No outcome recorded
Phase 3 NCT02173795 Oct 2002 → Jun 2003 asthma, chronic obstructive pulmonary disease Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT00274066 Oct 2002 → Sep 2003 chronic obstructive pulmonary disease Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT02182505 Sep 1998 → Jul 1999 asthma Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT02182479 Apr 1998 → Jun 1999 asthma Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT02173782 Feb 1998 → Apr 1999 chronic obstructive pulmonary disease Boehringer Ingelheim Completed No outcome recorded
Phase 3 NCT02177370 Feb 1990 → Oct 1996 asthma Boehringer Ingelheim Terminated No outcome recorded
Phase not applicable1 trial
NCT01933984 Aug 2013 → Jan 2019 chronic obstructive pulmonary disease Shin-hwar Wu Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT01095016 Comparator Mar 2010 → Sep 2012 asthma Taiwan Otsuka Pharm. Co., Ltd Completed No outcome recorded
Phase 41 trial
Phase 4 NCT00460577 Comparator Mar 2007 → Sep 2008 acute asthma Novartis Completed No outcome recorded
Phase not applicable2 trials
NCT05183841 Comparator Apr 2022 → Nov 2024 bronchiectasis University of Sao Paulo General Hospital Unknown No outcome recorded
NCT02790047 Background Oct 2016 → Jan 2018 chronic obstructive pulmonary disease Khon Kaen University Unknown No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as Fenoterol “Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours” NCT01933984
10

“50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d” NCT02173782

“50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide” NCT02182479

fenoterol hydrobromide 50μg + ipratropium bromide 20μg” NCT02176187

“Ipratropium+fenoterol (inhaler)” NCT02790047

NCT02054299

NCT00274066

NCT00460577

NCT05183841

NCT02177370

NCT05294965

Known as Berotec “To evaluate acute effect of single dose of ipratropium (Atrovent) or fenoterol (Berotec) in comparison to placebo when given to COPD patients on pharmacodynamic steady state of...” NCT00274066
1

NCT01095016

Known as fenoterol (Berotec)(0.1mg/puff) fenoterol (Berotec)(0.1mg/puff)NCT01933984
Known as fenoterol hydrobromide “Study to compare the lung and oropharyngeal deposition of Berodual® (fenoterol hydrobromide 50μg + ipratropium bromide 20μg /1x puff) delivered via the Respimat® inhaler and...” NCT02176200
2

“Berodual® Respimat® (20 µg ipratropium bromide + 50 µg fenoterol hydrobromide per actuation for 49 days)” NCT02173795

“50 µg Fenoterol Hydrobromide + 20 µg Ipratropium Bromide” NCT02182505

Action Activate “selective beta-2-adrenergic agonist” NCT05294965
Route Inhaled “single dose (2 Puffs) of the Shortacting Anticholinergic Ipratropium Bromide (40μg) and the Short-acting Beta-adrenergic Fenoterol (200μg)” NCT00274066